TNF inhibitor Tx tactics.
| Publicado en: | Dermatology Times Vol. 38; no. 5; pp. 38 - 40 |
|---|---|
| Autor principal: | |
| Formato: | case study pictorial Journal Article |
| Publicado: |
MJH Life Sciences
May2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123060300&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 123060300 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01966197 DTI jtl: Dermatology Times issn: 01966197 maglogo: N pubinfo: dt: May2017 vid: 38 iid: 5 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 123060300 123060300 123060300 123060300 ppf: 38 ppct: 2 formats: tig: atl: TNF inhibitor Tx tactics. aug: au: JESITUS, JOHN sug: subj: Tumor Necrosis Factor Adverse Effects Adalimumab Administration and Dosage Dermatology International Classification of Diseases Female Middle Age Pyoderma Gangrenosum Therapy Infliximab Therapeutic Use Drug Approval United States Food and Drug Administration Middle Aged: 45-64 years Female pubtype: Trade Publication doctype: case study pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|